Reviva Pharmaceuticals (NASDAQ:RVPH) Given Speculative Buy Rating at Benchmark

Benchmark reissued their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $17.00 price target on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $20.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, March 25th.

Reviva Pharmaceuticals Trading Down 4.3 %

Shares of NASDAQ:RVPH opened at $3.33 on Tuesday. Reviva Pharmaceuticals has a 52 week low of $2.67 and a 52 week high of $9.25. The company’s 50 day moving average is $3.73 and its two-hundred day moving average is $4.18. The company has a market cap of $92.97 million, a PE ratio of -1.99 and a beta of -0.02.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RVPH. Raymond James & Associates purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $34,000. Renaissance Technologies LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $31,000. BlackRock Inc. purchased a new position in shares of Reviva Pharmaceuticals in the 3rd quarter valued at $133,000. Jane Street Group LLC acquired a new stake in Reviva Pharmaceuticals during the 3rd quarter worth $27,000. Finally, Geode Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 86.3% during the 4th quarter. Geode Capital Management LLC now owns 145,430 shares of the company’s stock worth $618,000 after purchasing an additional 67,355 shares during the period. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.